mevastatin has been researched along with Hyperlipoproteinemia Type III in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Averna, M; Blom, D; Cefalù, AB; Ciccarese, M; Cossu, M; Croyal, M; Dallinga-Thie, G; Guédon, A; Hovingh, K; Lambert, G; Passard, M; Peter, J; Pintus, P; Pisciotta, L; Prampart-Fauvet, S; Raal, F; Santos, RD; Sjouke, B; Thedrez, A | 1 |
1 other study(ies) available for mevastatin and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type III; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Proprotein Convertase 9; Receptors, LDL; Serine Proteinase Inhibitors; Young Adult | 2016 |